London-based Isomorphic Labs has raised $2.1 billion in a Series B funding round to accelerate the development of its AI-powered drug discovery platform and expand its therapeutic pipeline toward clinical trials.
The round was led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
Building An AI-Native Drug Discovery Platform
Founded in 2021 by Demis Hassabis and led alongside President Max Jaderberg, Isomorphic Labs is developing an AI-first platform designed to transform how medicines are discovered and developed.
The company builds on advances in computational biology and artificial intelligence, extending beyond AlphaFold to design and predict novel molecules across multiple disease areas and therapeutic approaches.
Its core platform, IsoDDE, is designed to support end-to-end drug discovery through AI-driven modelling, simulation, and molecular design.
Advertisement
Expanding Toward Clinical Development
The new funding will support the continued development of the company’s AI drug design engine, expand internal therapeutic programs toward clinical-stage development, and scale teams across AI research, engineering, and clinical operations.
Isomorphic Labs aims to make drug discovery more data-driven and programmable, reducing the time and complexity traditionally associated with identifying viable treatment candidates.
The company is already collaborating with major pharmaceutical groups including Novartis, Eli Lilly and Company, and Johnson & Johnson as part of its broader commercial and research strategy.
AI And The Future Of Medicine
According to Max Jaderberg, the company’s AI systems have already demonstrated strong progress across internal programs by helping identify potential drug candidates with significantly greater speed and efficiency.
The company believes AI-driven drug design could fundamentally reshape the pharmaceutical industry by enabling more scalable, repeatable, and precise medicine development across a wide range of diseases.
About Isomorphic Labs
Isomorphic Labs is an AI-first drug discovery company headquartered in London, with additional operations in Cambridge and Lausanne. Founded in 2021, the company develops advanced AI systems for molecular prediction and therapeutic design, aiming to accelerate the discovery and development of new medicines across multiple disease areas.
